IL6 and congenital rubella syndrome: Tocilizumab, an IL-6 receptor antagonist which can clear overloaded IL-6 and reduce inflammatory damage, has been approved by the Food and Drug Administration (FDA) for the treatment of CRS following CAR-T cell therapy.